USPTO Examiner TRAN SUSAN T - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19301647IMMEDIATE RELEASE MULTILAYER TABLETAugust 2025December 2025Allow410NoNo
19263736METHOD OF TREATING CANCER USING CaV2O6/CaSiO3/g-C3N4 NANOCOMPOSITEJuly 2025September 2025Allow300NoNo
19238194PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEJune 2025March 2026Allow920YesNo
19174583TAMPER RESISTANT DOSAGE FORMSApril 2025July 2025Allow310NoNo
19047536NOVEL FORMULATION FOR LACOSAMIDEFebruary 2025August 2025Allow610YesNo
18953603TAMPER RESISTANT DOSAGE FORMSNovember 2024February 2025Allow310NoNo
18921291PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEOctober 2024March 2025Allow510YesNo
18830440COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALSSeptember 2024March 2025Allow620YesNo
18801899CENTANAFADINE MULTIPHASIC CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONAugust 2024November 2025Allow1540YesNo
18794390ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONSAugust 2024February 2025Allow620YesNo
18760150FAST DISINTEGRATING TABLETJuly 2024October 2025Allow1520NoNo
18666141SHELF-STABLE FORMULATIONS OF BENZOYL PEROXIDE AND METHODS OF PRODUCING SAMEMay 2024March 2025Abandon1010NoNo
18661506TCM THROAT TEA METHOD AND COMPOSITIONMay 2024September 2025Abandon1720YesNo
18629431ALLERGENIC PROTEIN FORMULATIONS FOR IMMUNOTHERAPYApril 2024February 2026Allow2220YesNo
18618702COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALSMarch 2024August 2024Allow420YesNo
18609809OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOFMarch 2024December 2025Allow2120YesNo
18690069METAL-GLYCEROL DECORATED ANTIMICROBIAL POLYMER COMPOSITEMarch 2024September 2025Abandon1930YesYes
18585349Long Acting Injectable Formulation Comprising Risperidone And Biodegradable PolymersFebruary 2024April 2025Allow1320YesNo
18434155COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINEFebruary 2024September 2024Allow710YesNo
18419135INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACTJanuary 2024November 2025Allow2210NoNo
18411236NOVEL IBUPROFEN AND ACETAMINOPHEN COMPOSITIONJanuary 2024June 2025Abandon1810NoNo
18576386MICROBIAL TREATMENT SOLUTION AND METHOD OF PRODUCING MICROBIAL TREATMENT SOLUTIONJanuary 2024August 2024Allow810NoNo
18518823METHOD OF MAKING GOLD NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAMENovember 2023July 2024Allow820YesNo
18510816Multifunctional Nanoparticles For Prevention And Treatment Of AtherosclerosisNovember 2023April 2025Abandon1710NoNo
18510590IMMEDIATE RELEASE MULTILAYER TABLETNovember 2023December 2025Abandon2530YesNo
18510585IMMEDIATE RELEASE MULTILAYER TABLETNovember 2023January 2025Allow1410NoNo
18560039TRIMODAL, PRECISION-TIMED PULSATILE RELEASE TABLETNovember 2023March 2026Allow2810YesNo
18387599COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURESNovember 2023June 2025Abandon2010NoNo
18495149COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONOctober 2023September 2024Allow1120NoNo
18491946NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATIONOctober 2023December 2025Allow2610NoNo
18489379METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALSOctober 2023March 2025Abandon1710NoNo
18480820PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTINOctober 2023March 2026Abandon3010NoNo
18478797LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOFSeptember 2023March 2024Allow620YesNo
18371932PREPARATION CONTAINING SAXAGLIPTIN AND METHOD FOR PRODUCING THE SAMESeptember 2023August 2025Allow2230NoNo
18464911Nicotine TabletSeptember 2023October 2024Allow1310YesNo
182444245-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMSSeptember 2023January 2026Abandon2820NoYes
18463498AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOFSeptember 2023January 2025Allow1630NoNo
18229914COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURESAugust 2023November 2024Abandon1510NoNo
18363002ANTIMICROBIAL COMPOSITION COMPRISING AN ALKYLDIMETHYLBENZYLAMMONIUM COMPOUNDAugust 2023August 2025Allow2500YesNo
18217994METHODS FOR TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONSJuly 2023February 2026Abandon3110NoNo
18213143ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOFJune 2023February 2025Allow2020NoNo
18327229IMMEDIATE RELEASE MULTILAYER TABLETJune 2023December 2023Allow610YesNo
18314348AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOFMay 2023September 2023Allow410NoNo
18136974Method for Controlling Hematophagous or Sap-Feeding ArthropodsApril 2023January 2025Allow2110NoNo
18304246COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONApril 2023September 2023Allow510YesNo
18119192THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEMarch 2023September 2025Abandon3120NoNo
18024452Liquid Embolic Compositions with Controlled Release of Radiopaque and Therapeutic Compounds and Methods of Using the SameMarch 2023December 2025Allow3410YesNo
18175212Acetaminophen Formulation With Protection Against Toxic Effects of OverdoseFebruary 2023April 2025Abandon2610NoNo
18169402PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEFebruary 2023August 2024Allow1830YesNo
18021053METHOD FOR TREATING DERMATITISFebruary 2023January 2026Abandon3510NoNo
18102471METHOD OF ENHANCING 5-HYDROXYTRYPTOPHAN (5-HTP) EXPOSUREJanuary 2023May 2025Allow2720YesNo
18160953DELIVERY SYSTEMS FOR CONTROL OF BLEEDING IN TRANSURETHRAL PROSTATECTOMYJanuary 2023August 2025Allow3120YesNo
18102014COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURESJanuary 2023September 2023Allow710YesNo
18006141FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOFJanuary 2023March 2026Abandon3810NoNo
18155240PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR TREATMENT OF PAINJanuary 2023September 2023Allow720YesNo
18005179ORAL SUSTAINED-RELEASE COMPOSITION FOR INSOLUBLE DRUG, AND PREPARATION METHOD THEREOFJanuary 2023October 2025Allow3310NoNo
18013801METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAMEDecember 2022December 2025Allow3610NoNo
18009173INGESTIBLE DEVICE HAVING A SPIKE ASSEMBLYDecember 2022May 2025Abandon2900NoNo
18000166PRALSETINIB PHARMACEUTICAL COMPOSITIONSNovember 2022March 2026Allow3911YesNo
18070341COMBINATION SOLID ORAL DOSAGE FORMS OF GONADOTROPIN-RELEASING HORMONE ANTAGONISTSNovember 2022October 2025Allow3401NoNo
17922914NOVEL EXTENDED RELEASE COMPOSITION OF 2-(2- AMINOTHIAZOL-4-YL)-N-[4-(2{[(2R)-2-HYDROXY-2-PHENYLETHYL] AMINO} ETHYL) PHENYL] ACETAMIDENovember 2022December 2025Allow3820YesNo
17922623NEW COMPOSITIONS FOR ORAL OR NASAL USENovember 2022December 2025Allow3821YesNo
17963013METHOD AND DEVICE FOR IN VIVO TISSUE REGENERATION ON THE INTERIOR SURFACE OF HOLLOW ORGANSOctober 2022June 2025Allow3220YesNo
17938703RE-TREATMENT FOR OPHTHALMIC CORRECTION OF REFRACTIONOctober 2022July 2025Allow3311YesNo
17916618METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATIONOctober 2022March 2025Allow3000YesNo
17957715COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE DEFICIENCY AND INFLAMMATIONSeptember 2022September 2025Allow3620YesNo
17916195COMPOSITION HAVING IMPROVED VOLUNTARY ACCEPTANCESeptember 2022October 2025Allow3710YesNo
17936361Novel Dietary SupplementsSeptember 2022June 2024Allow2120NoNo
17912638USE OF SLOW-RELEASING HYDROGEN SULFIDE ORGANIC DONOR ADT-OH IN THE PREPARATION OF DRUGS FOR TREATING NERVOUS SYSTEM DISEASESSeptember 2022October 2025Allow3710NoNo
17945890INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACTSeptember 2022January 2024Allow1610NoNo
17944494EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASESeptember 2022August 2025Abandon3530NoNo
17902689STACKED TISSUE ENCAPSULATION DEVICE SYSTEMS WITH OR WITHOUT OXYGEN DELIVERYSeptember 2022February 2024Allow1800YesNo
17887246ORAL FOOD CHALLENGE MEAL FORMULATIONSAugust 2022September 2024Allow2530YesNo
178776995-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMSJuly 2022April 2023Allow920YesNo
17869978WOUND DRESSING AND A METHOD FOR PRODUCING THE SAMEJuly 2022December 2023Allow1710YesNo
17855242IMMEDIATE RELEASE MULTILAYER TABLETJune 2022March 2023Allow910NoNo
17784453INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACTJune 2022April 2023Allow1110NoNo
17837501ORAL ADMINISTRATION OF KETAMINEJune 2022January 2026Allow4340NoNo
17757043DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASEJune 2022May 2023Allow1120YesNo
17835435OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOFJune 2022January 2026Allow4321NoNo
17833638SILICATE CONTAINING COMPOSITIONS AND METHODS OF TREATMENTJune 2022July 2024Abandon2610NoNo
17832229MICROPARTICLES CONTAINING LEUPROLIDE AND METHOD FOR PRODUCING THE SAMEJune 2022March 2024Allow2120NoYes
17829908PHARMACEUTICAL COMPOSITIONSJune 2022July 2023Allow1420YesNo
17664513LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOFMay 2022September 2023Allow1610NoNo
17602393METHOD FOR CONTINUOUSLY PRODUCING AN ACTIVE INGREDIENT GRANULATEMay 2022October 2025Allow4810NoNo
17775245POLYMERIC NANOPARTICLES THAT TARGET LIVER SINUSOIDAL ENDOTHELIAL CELLS TO INDUCE ANTIGEN-SPECIFIC IMMUNE TOLERANCEMay 2022October 2025Allow4101NoNo
17735741AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOFMay 2022June 2023Abandon1320YesNo
17735784AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOFMay 2022June 2023Abandon1320YesNo
17773058USE OF NEUROSPORENE TO PROTECT THE SKIN FROM THE HARMFUL EFFECTS OF BLUE LIGHTApril 2022September 2025Abandon4010NoNo
17772336FRAGRANCE OR FLAVOR COMPOSITIONApril 2022September 2025Allow4120NoNo
17716790AN EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINEApril 2022December 2022Allow910YesNo
17763740COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF PANCREATITISMarch 2022May 2025Abandon3810NoNo
17702850Multifunctional Nanoparticles For Prevention And Treatment Of AtherosclerosisMarch 2022January 2024Abandon2220NoNo
17696984NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATIONMarch 2022July 2023Allow1620NoNo
17695881Oxcarbazepine Extended Release Dosage FormMarch 2022January 2024Allow2240YesNo
17417645EXTERNAL PREPARATIONMarch 2022June 2025Allow4720YesNo
17687160CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTSMarch 2022March 2025Allow3620NoNo
17683732OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOFMarch 2022June 2024Abandon2710NoNo
17638368ANTI-PATHOGEN COMPOSITIONSFebruary 2022July 2024Allow2810YesNo
17634791ORAL PHARMACEUTICAL COMPOSITIONFebruary 2022September 2024Abandon3120NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TRAN, SUSAN T.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
27
Examiner Affirmed
13
(48.1%)
Examiner Reversed
14
(51.9%)
Reversal Percentile
79.9%
Higher than average

What This Means

With a 51.9% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
248
Allowed After Appeal Filing
68
(27.4%)
Not Allowed After Appeal Filing
180
(72.6%)
Filing Benefit Percentile
40.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 27.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner TRAN, SUSAN T - Prosecution Strategy Guide

Executive Summary

Examiner TRAN, SUSAN T works in Art Unit 1615 and has examined 1,331 patent applications in our dataset. With an allowance rate of 61.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner TRAN, SUSAN T's allowance rate of 61.1% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by TRAN, SUSAN T receive 2.38 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TRAN, SUSAN T is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.2% benefit to allowance rate for applications examined by TRAN, SUSAN T. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.5% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 83.4% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 57.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.7% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 16.2% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.